IP Library Granted Patent US 10,543,219
Granted Patent B2
US 10,543,219 · App. 15/723,985 · Granted Jan 28, 2020

Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same

Inventors: Robert E. Dudley (Murfreesboro, TN); Panayiotis P. Constantinides (Gurnee, IL)
Assignee: Clarus Therapeutics, Inc.
A61K31/568A61K9/0053A61K9/0095A61K9/107A61K47/12A61K47/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,543,219
App. No.
15/723,985
Granted
Jan 28, 2020
Kind
B2
Abstract

A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.

Claims (32)

1. A method of treating testosterone deficiency or its symptoms in a male in need thereof comprising:

daily administering to said male about 475 mg testosterone undecanoate,

wherein said testosterone undecanoate is administered in an oral pharmaceutical composition with food, and

wherein said oral pharmaceutical composition comprises:

18-22 percent by weight of solubilized testosterone undecanoate;

50-55 percent by weight of oleic acid;

15-17 percent by weight of polyoxyethylene (40) hydrogenated castor oil; and

10-15 percent by weight of a mixture of borage seed oil and peppermint oil.

2. The method of claim 1 , wherein said oral pharmaceutical composition comprises about 20 percent by weight testosterone undecanoate.

3. The method of claim 1 , wherein said oral pharmaceutical composition comprises:

19.8 percent by weight of solubilized testosterone undecanoate;

51.6 percent by weight of oleic acid;

16.1 percent by weight of polyoxyethylene (40) hydrogenated castor oil;

10 percent by weight of borage seed oil; and

2.5 percent by weight of peppermint oil.

4. The method of claim 3 , wherein said oral pharmaceutical composition further comprises one or more antioxidants.

5. The method of claim 1 , wherein said oral pharmaceutical composition is in the form of a capsule.

6. The method of claim 1 , wherein said administration results in a serum testosterone C ave in said male in the range of from about 300-1100 ng/dL.

7. The method of claim 1 , wherein said oral pharmaceutical composition is administered once daily.

8. The method of claim 1 , wherein said oral pharmaceutical composition is administered twice daily.

9. The method of claim 8 , wherein said administration results in a serum testosterone C ave in said male in the range of from about 300-1100 ng/dL.

10. The method of claim 1 , wherein said male has primary hypogonadism.

11. A method of treating testosterone deficiency or its symptoms in a male having primary hypogonadism comprising:

daily administering to said male about 475 mg testosterone undecanoate,

wherein said testosterone undecanoate is administered in an oral pharmaceutical composition, and

wherein said oral pharmaceutical composition is administered twice daily with food and comprises:

19.8 percent by weight of solubilized testosterone undecanoate;

51.6 percent by weight of oleic acid;

16.1 percent by weight of polyoxyethylene (40) hydrogenated castor oil;

10 percent by weight of borage seed oil; and

2.5 percent by weight of peppermint oil.

12. The method of claim 11 , wherein said administration results in a serum testosterone C ave in said male in the range of from about 300-1100 ng/dL.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Dec 6, 2022
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO U.S. BANK NATIONAL ASSOCIATION
To: CLARUS THERAPEUTICS, INC.
Reel/Frame 062000/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2022
From: CLARUS THERAPEUTICS, INC.
To: TOLMAR, INC.
Reel/Frame 061774/0516 →
SECURITY INTEREST Recorded Mar 12, 2020
From: CLARUS THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 052099/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2017
From: DUDLEY, ROBERT E.; CONSTANTINIDES, PANAYIOTIS P.
To: CLARUS THERAPEUTICS, INC.
Reel/Frame 043795/0819 →
Continuity (5)
Continuation 15381430 · Dec 16, 2016
Continuation 14290540 · May 29, 2014
Continuation 13584958 · Aug 14, 2012
Continuation 12758770 · Apr 12, 2010
Related Publication 20180110786A1 · Apr 26, 2018
Cited By (1)
US 12,605,391